For patients who are prescribed ELREXFIO, Pfizer offers the support of Patient Access Navigators, through our Pfizer Oncology Together program, who provide personalized services for all aspects of treatment, including financial assistance resources, treatment support, and...
For patients who are prescribed ELREXFIO, Pfizer offers the support of Patient Access Navigators, through our Pfizer Oncology Together program, who provide personalized services for all aspects of treatment, including financial assistance resources, treatment support, and resources to nav...
Oncology Medical Affairs Undergraduate Who can apply? Applicants must be completing placement as part of a degree course at a UK University, either through Year in Industry/Industrial Placement or Gap Year. Please note that we only accept application forms. Please do not send over your CV ...
The Pfizer Oncology Together Co-Pay Savings Program for Injectables for ELREXFIO™, NIVESTYM®, NYVEPRIA™, RUXIENCE®, TRAZIMERA®, and ZIRABEV®is not valid for patients who are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medic...
Oncology is the only therapeutic area with an average regulatory review of less than 1 year; the 0.8-year duration is almost half as short as the cumulative total for all non-oncology indications (1.4 years). Urology drug candidates see the longest Phase 2 duration (5.0 years). Excluding ...
Xtandi (enzalutamide)– InNovember 2023, Astellas andPfizerannounced the FDA approved a supplemental New Drug Application (sNDA) for Xtandi following FDA expedited development and review programs (Priority Review designation, Fast Track designation, Real-time Oncology Review), based on...
application for patients across a wide range of cancers. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments, and licensing partners, Pfizer Oncology strives to cure or control cancer with breakthrough medicines, to deliver the right drug ...
Pfizer has never scored in one year with so many diverse products. In 2018, for example, when the company achieved four approvals, all of the blessings were for oncology drugs. Martin Mackay, Ph.D., now the co-founder of Connecticut biotech RallyBio who formerly guided the R&D ...
So the work for COVID happened in one of the six business units, and happened predominantly in the R&D domain of these clinical units. But at the same time the Oncology business unit and the Rare Disease business unit and the Internal Medicine business unit and all the other business units...
This application claims benefit under 35 USC 119(e) to Provisional Patent Application No. 61/097,902 filed Sep. 18, 2008. Claims: The invention claimed is: 1. A compound of Formula (I): wherein, R1 and R2 each independently represent H, halogen, CF3, C1-3 alkyl or C1-3 alkoxy; ...